Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.

Trends in Pharmacological Sciences
Byoung Dae LeeTed M Dawson

Abstract

Parkinson's disease (PD) is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. Although the etiology for most PD remains elusive, the identification of specific genetic defects in familial cases of PD and the signaling pathways governed by these genes has provided tremendous insight into PD pathogenesis. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are frequently found in familial and sporadic PD. Although current knowledge regarding the regulatory mechanisms of LRRK2 activation is limited, it is becoming increasingly evident that aberrant kinase activity of the pathologic mutants of LRRK2 is associated with neurodegeneration, suggesting that the kinase activity of LRRK2 is a potential therapeutic target. In addition, LRRK2 inhibitors might provide valuable tools to understand the pathophysiological and physiological roles of LRRK2 as well as the etiology of PD. We discuss here the potential and feasibility of targeting LRRK2 as a therapeutic strategy for PD.

References

Sep 5, 2002·Nature Reviews. Molecular Cell Biology·Kathleen A Gallo, Gary L Johnson
Jan 22, 2003·The Biochemical Journal·Jenny BainPhilip Cohen
Mar 20, 2004·Science·Martin E M NobleLouise N Johnson
Sep 27, 2005·Biochimica Et Biophysica Acta·Marie A BogoyevitchAlbert J Ketterman
Oct 26, 2005·Cellular Signalling·Daniel KorrBertram Weiss
Jan 27, 2006·Annals of Neurology·Owen A RossDennis W Dickson
Feb 18, 2006·Nature Chemical Biology·Adrian Whitty, Gnanasambandam Kumaravel
Jun 6, 2006·Neurobiology of Disease·Elisa GreggioMark R Cookson
Jul 11, 2006·The Journal of Clinical Investigation·Joseph M SavittTed M Dawson
Sep 19, 2006·Nature Neuroscience·Wanli W SmithChristopher A Ross
Nov 23, 2006·Neuron·David MacLeodAsa Abeliovich
Nov 23, 2006·Annals of Neurology·Saskia BiskupValina L Dawson
Mar 10, 2007·Current Biology : CB·Aisa Sakaguchi-NakashimaNaoki Hisamoto
Apr 20, 2007·Biochemical and Biophysical Research Communications·Patrick A LewisMark R Cookson
May 11, 2007·Acta Neurologica Scandinavica·Amos D Korczyn
Aug 28, 2007·Nature Biotechnology·Marcus BantscheffGerard Drewes
Sep 14, 2007·The Biochemical Journal·Jenny BainPhilip Cohen
Sep 21, 2007·Neurology·UNKNOWN Parkinson Study Group PRECEPT Investigators
Feb 9, 2008·Proceedings of the National Academy of Sciences of the United States of America·Zhaohui LiuWanli W Smith
Mar 28, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Lizhen WangHuaibin Cai
Apr 12, 2008·Nature Reviews. Drug Discovery·David M GoldsteinPatrick P Zarrinkar
Nov 26, 2008·Biochemical and Biophysical Research Communications·Jason P Covy, Benoit I Giasson
Apr 29, 2009·Biochemical and Biophysical Research Communications·Laurie J Reichling, Steven M Riddle
Jun 16, 2009·Lancet·Andrew J LeesTamas Revesz
Jul 25, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shamol SahaBenjamin Wolozin
Sep 11, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Chee-Hoe NgKah-Leong Lim
Oct 15, 2009·The Journal of Biological Chemistry·Saurabh SenAndrew B West
Dec 31, 2009·PloS One·Nathan D JorgensenWilliam T Dauer
Apr 14, 2010·PLoS Genetics·Yulan XiongDarren J Moore
May 12, 2010·Archives of Neurology·Justus C Dächsel, Matthew J Farrer
Jun 16, 2010·Neuron·Ted M DawsonValina L Dawson
Feb 11, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Giovanni PiccoliMarius Ueffing

❮ Previous
Next ❯

Citations

Apr 11, 2014·Human Molecular Genetics·Farinaz AfsariAlex R Wade
Jun 25, 2014·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Iakov N Rudenko, Mark R Cookson
Oct 25, 2013·Expert Opinion on Drug Discovery·Mary Konsolaki
Sep 20, 2012·Biochemical Society Transactions·Yulan XiongTed M Dawson
Apr 15, 2017·Bioorganic & Medicinal Chemistry Letters·Emanuela GanciaDavid E Clark
Dec 13, 2016·CNS Neuroscience & Therapeutics·Qi QinHui Zhang
Sep 17, 2013·Annals of Neurology·C Warren Olanow, Anthony H V Schapira
Feb 8, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Fabrizio Stocchi, C Warren Olanow
Oct 31, 2014·Annals of Clinical and Translational Neurology·Hui-Fang LiuShu-Leong Ho
Jul 20, 2016·Nature Communications·Jay PenneyA Pejmun Haghighi
Sep 14, 2019·Future Medicinal Chemistry·Sofia DomingosRui Moreira
Sep 22, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Elvira Valera, Eliezer Masliah
Apr 23, 2015·The FEBS Journal·Rebecca WallingsRina Bandopadhyay
Oct 11, 2016·Proteomics·Un-Beom Kang, Jarrod A Marto
Aug 28, 2020·Frontiers in Cellular Neuroscience·Andrea ManciniPaolo Calabresi
Jan 26, 2017·Frontiers in Aging Neuroscience·Joseph M ThomasWanli W Smith
Aug 19, 2017·Scientific Reports·Kushal SejwalJean-Marc Taymans
Jun 7, 2013·Expert Review of Neurotherapeutics·Linda MacArthurHoward J Federoff
Dec 4, 2020·Cells·Ga Ram Jeong, Byoung Dae Lee
Apr 4, 2021·Genes·Eun-Mi Hur, Byoung Dae Lee
Jun 10, 2021·Cell·Alexander MyasnikovJi Sun
Oct 16, 2012·ACS Medicinal Chemistry Letters·Hwan Geun ChoiNathanael S Gray
Jan 10, 2013·ACS Medicinal Chemistry Letters·Bryan K ChanZachary K Sweeney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.